103 related articles for article (PubMed ID: 35158802)
1. Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer.
Ma SJ; Serra LM; Yu B; Farrugia MK; Iovoli AJ; Yu H; Yao S; Oladeru OT; Singh AK
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158802
[TBL] [Abstract][Full Text] [Related]
2. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
[TBL] [Abstract][Full Text] [Related]
3. Racial/Ethnic Differences in Pathologic Complete Response to Neoadjuvant Chemotherapy and Survival Among Early-Stage, Erb-B2 Receptor Tyrosine Kinase 2-Low Breast Cancer Patients.
Freeman JQ; Li JL; Omoleye OJ
J Breast Cancer; 2024 Feb; 27(1):54-60. PubMed ID: 38233338
[TBL] [Abstract][Full Text] [Related]
4. Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients.
Paster IC; Zeng J; Recio-Boiles A; Chipollini J
Urology; 2023 Aug; 178():105-113. PubMed ID: 37230271
[TBL] [Abstract][Full Text] [Related]
5. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
6. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
[TBL] [Abstract][Full Text] [Related]
7. Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
Woriax HE; Thomas SM; Plichta JK; Rosenberger LH; Botty van den Bruele A; Chiba A; Hwang ES; DiNome ML
J Clin Oncol; 2024 May; 42(14):1635-1645. PubMed ID: 38394476
[TBL] [Abstract][Full Text] [Related]
8. Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016.
Acheampong T; Kehm RD; Terry MB; Argov EL; Tehranifar P
JAMA Netw Open; 2020 Aug; 3(8):e2013226. PubMed ID: 32804214
[TBL] [Abstract][Full Text] [Related]
9. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB).
Fayanju OM; Ren Y; Thomas SM; Greenup RA; Plichta JK; Rosenberger LH; Tamirisa N; Force J; Boughey JC; Hyslop T; Hwang ES
Ann Surg; 2018 Oct; 268(4):591-601. PubMed ID: 30048319
[TBL] [Abstract][Full Text] [Related]
10. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Warner ET; Ballman KV; Strand C; Boughey JC; Buzdar AU; Carey LA; Sikov WM; Partridge AH
Breast Cancer Res Treat; 2016 Aug; 159(1):109-18. PubMed ID: 27449492
[TBL] [Abstract][Full Text] [Related]
11. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB).
Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B
Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.
Ma SJ; Serra LM; Yu B; Bartl AJ; Farrugia MK; Oladeru OT; Singh AK
Breast Cancer Res Treat; 2021 Oct; 189(3):737-745. PubMed ID: 34519904
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype.
Parise C; Caggiano V
J Breast Cancer; 2016 Jun; 19(2):112-21. PubMed ID: 27382386
[TBL] [Abstract][Full Text] [Related]
14. The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response.
Mandish SF; Gaskins JT; Yusuf MB; Amer YM; Eldredge-Hindy H
Acta Oncol; 2020 Oct; 59(10):1210-1217. PubMed ID: 32716227
[TBL] [Abstract][Full Text] [Related]
15. Race and ethnicity are among the predisposing factors for fetal malpresentation at term.
Bar-El L; Eliner Y; Grunebaum A; Lenchner E; Wasden SW; Chervenak FA; Bornstein E
Am J Obstet Gynecol MFM; 2021 Sep; 3(5):100405. PubMed ID: 34091061
[TBL] [Abstract][Full Text] [Related]
16. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
[TBL] [Abstract][Full Text] [Related]
17. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
Chavez-Macgregor M; Litton J; Chen H; Giordano SH; Hudis CA; Wolff AC; Valero V; Hortobagyi GN; Bondy ML; Gonzalez-Angulo AM
Cancer; 2010 Sep; 116(17):4168-77. PubMed ID: 20564153
[TBL] [Abstract][Full Text] [Related]
18. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii H; Winer EP; Freedman RA
Breast Cancer Res Treat; 2015 Jun; 151(3):697-707. PubMed ID: 26022349
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
